What is the market's earnings forecast for Revvity next quarter?

What is Revvity's gross profit margin?

What guidance did Revvity's management provide for the next earnings period?

What is Revvity's latest dividend and current dividend yield?

What were the key takeaways from Revvity’s earnings call?

What does Revvity do and what are its main business segments?

What factors drove the changes in Revvity's revenue and profit?

What is the revenue and EPS growth rate for Revvity year over year?

- **Revenue Growth**: FY2025 organic +3%, Q4 Diagnostics +7%, Life Sciences flat. 2026 guide: 2-3% organic, $2.96-2.99B revenue. 
- **AI Expansion**: Launch of Signals Xynthetica AI platform with Lilly collaboration. 
- **Share Buybacks**: $800M in 2025, total $1.5B since 2023. 
- **China Risks**: Diagnostics China business <5% of revenue, cautious on DRG-related volumes. 
- **2026 EPS**: $5.35-5.45, with 28% operating margin and 1% FX tailwind.

**【CEO Summary Section】**
- **Q4 2025 Performance**: Revenue of $772M, 4% organic growth, with Diagnostics up 7% and Life Sciences flat. FY2025 organic growth 3%, adjusted EPS $5.06 (3% YoY growth). 
- **Segment Highlights**: Diagnostics driven by immunodiagnostics (+7%) and reproductive health (+mid-single digits). Life Sciences reagents flat, instruments flat Q4 but +14% sequentially. 
- **2026 Outlook**: 2-3% organic growth, $2.96-2.99B revenue, $5.35-5.45 EPS. Includes 75bps from ACD/Labs acquisition and 1% FX tailwind. 
- **Strategic Initiatives**: Launch of AI models-as-a-service (Signals Xynthetica) with Lilly collaboration. Repurchased $800M shares in 2025, total $1.5B since 2023. 

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Adjusted operating margin 29.7%, adjusted EPS $1.70 (vs. $1.59 guidance). FY2025 free cash flow $515M (87% conversion). 
- **2026 Guidance**: 28% adjusted operating margin, $5.35-5.45 EPS. Q1 2026 margin ~23% due to extra week, tariffs, and cost programs. 
- **Capital Deployment**: $800M share buybacks in 2025, $1.5B total since 2023. ACD/Labs acquisition adds $20M+ revenue. 

**【Q&A Key Highlights】**
- **Organic Growth Drivers**: Pharma/biotech funding recovery, MFN deals, and academic/gov. market normalization. Instruments and reagents growth tied to preclinical demand. 
- **China Risks**: Diagnostics China business <5% of revenue, but cautious on DRG-related volume pressures. 
- **AI Upside**: Signals Xynthetica could accelerate drug discovery timelines, with Lilly collaboration as key proof point. 
- **Margin Leverage**: 2026 cost efficiency programs to expand margins if organic growth exceeds 3%.

Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript

- **Q3 Strong Performance**: 1% organic growth, $1.18 EPS beat, and 26.1% margins despite China Diagnostics headwinds.
- **AI-Driven Innovation**: New AI products launched, internally improving efficiency by 3x in sales and 5-10% in R&D timelines.
- **2026 Outlook**: 2-3% growth, 28% margins, and high single-digit EPS growth, supported by $1B buyback authorization.
- **China Risks**: Diagnostics down 20% YoY in China, but ex-China Diagnostics up high single digits.
- **Software Resilience**: Signals ARR >40%, APV 12%, and net retention >110%, despite 20%+ comp in 2026.

**【CEO Summary Section】**
- **Q3 Performance**: 1% organic revenue growth, driven by 20% year-over-year growth in the Signals software business and mid-single-digit growth in reproductive health. Adjusted EPS of $1.18 exceeded expectations by $0.05.
- **AI Initiatives**: Launched new AI-based products (e.g., Signals Synergy, Transcribe AI) and internally deployed AI tools, improving sales lead conversion rates by 3x and reducing software development timelines by 5-10%.
- **Cash Flow & Buybacks**: Generated $120M free cash flow and repurchased $205M in shares, bringing total buybacks since 2023 to 12.5M shares (10% of outstanding shares). Received a new $1B share repurchase authorization.
- **2026 Outlook**: Guided for 2-3% organic growth, 28% adjusted operating margins, and high single-digit EPS growth, assuming normalization of customer activity and continued cost containment.

**【CFO Financial Commentary】**
- **Q3 Financials**: Revenue of $699M, 26.1% adjusted operating margins (down 220bps YoY due to tariffs and China Diagnostics weakness). Free cash flow conversion of 88%.
- **China Impact**: Diagnostics business in China declined 20% YoY due to DRG reforms, but ex-China Diagnostics grew high single digits. Life Sciences Solutions business in China grew low single digits.
- **Below-the-Line**: Adjusted tax rate of 15%, net interest expense of $22M, and diluted shares of 115.5M.
- **2026 Guidance**: Organic growth 2-3%, adjusted operating margins 28%, and EPS growth driven by lower share count and stable below-the-line items.

**【Q&A Highlights】**
- **China Diagnostics**: Ex-China Diagnostics grew high single digits, but China remains a headwind with 20-25% YoY declines expected through Q2 2026. Localization efforts (e.g., >50% of IDX manufacturing in China) mitigate risks.
- **Software Growth**: Signals business faces 20%+ comp in 2026 but expects mid-single-digit growth with new NPIs (e.g., BioDesign, LabGistics). ARR, APV, and net retention rates remain strong (>110%).
- **Reagents & Instruments**: Reagents were modestly below expectations in Q3, but pharma/biotech instrument activity picked up in October. 2026 guidance assumes low single-digit growth in Life Sciences Solutions.
- **AI Impact**: AI adoption by customers could increase demand for reagents and instruments in the short term, while Signals' AI-driven drug discovery tools position Revvity for long-term growth.

Revvity, Inc. (RVTY) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 3% organic growth, with Life Sciences up 4% and Diagnostics 2% despite China headwinds.
- **Challenges**: China immunodiagnostics down 15-20% due to DRG policy, impacting 6% of revenue.
- **Margins**: 2026 operating margin baseline of 28%, with expansion potential tied to growth.
- **Strategic Moves**: $450M share buybacks, new IDS i20 platform, and ESG AAA rating.
- **Tariff Mitigation**: Operational actions offsetting tariff impacts, with EU deal adding limited 2025 pressure.

**【CEO Summary Section】**
- **Overall Performance**: 3% organic revenue growth, driven by 4% growth in Life Sciences and 2% in Diagnostics. Adjusted EPS of $1.18 exceeded expectations.
- **Life Sciences Strength**: Signals software grew 30% YoY with record orders. Life Sciences reagents saw 5 consecutive quarters of growth.
- **Diagnostics Challenges**: China immunodiagnostics down 15-20% YoY due to DRG policy changes. Global Diagnostics growth tempered by China headwinds.
- **Strategic Actions**: $450M in share buybacks YTD, new IDS i20 platform launch, and ESG rating upgrade to AAA.
- **Cash Flow**: $115M free cash flow, 90% conversion of adjusted net income YTD.

**【CFO Financial Commentary】**
- **Q2 Results**: Revenue $720M, 3% organic growth. Operating margin 26.6%, down 210bps YoY due to FX and tariffs.
- **Updated Guidance**: 2-4% organic growth for 2025, adjusted EPS $4.85-4.95. 2026 operating margin baseline of 28% with potential expansion.
- **Tariff Mitigation**: Operational actions offset tariff impacts. EU tariff deal may add $0.03-0.05 pressure, with mitigation underway.
- **FX Impact**: 1% tailwind to revenue for 2025, minimal P&L flow-through.

**【Q&A Highlights】**
- **China DRG Policy**: Expected 15-20% decline in immunodiagnostics, offset by single-plex test growth. 6% of total revenue affected.
- **2026 Margins**: 28% operating margin baseline, expansion tied to organic growth rate.
- **Tariff Outlook**: EU tariffs may impact 2025, but long-term manufacturing adjustments planned.
- **Life Sciences Trends**: Reagents growth stable, instruments cautious due to capital spending environment.
- **Reproductive Health**: Gel launch driving high single-digit growth in Q4, offsetting newborn screening headwinds.

Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript

- **Resilient Q1 Growth**: 4% organic revenue driven by 5% Diagnostics and 20%+ software growth.
- **Tariff Mitigation Success**: $135M gross impact reduced to 60bp margin headwind via supply chain shifts.
- **Software Standout**: Signals ARR/APV metrics exceed 2024 levels; LabGistics launch upcoming.
- **China Stability**: Low single-digit growth with Diagnostics outperforming Life Sciences.
- **Cash Deployment**: $154M share buybacks; 97% free cash flow conversion.
- **Full Year Confidence**: Reaffirmed $4.90-$5.00 EPS and 3%-5% organic growth guidance.

**【CEO Summary Section】**
- Q1 2025 organic revenue growth of 4%, driven by resilient Diagnostics (5%) and strong software (20%+ YoY) performance.
- Tariff mitigation actions expected to offset $135M gross impact, with net 60bp margin headwind for the year.
- U.S. academic demand choppiness (-low single digits) offset by software and reproductive health growth.
- Signals software pipeline includes LabGistics and biologic-related launches in coming quarters.
- Free cash flow conversion at 97%, with $154M share buybacks in Q1.

**【CFO Financial Commentary】**
- Q1 revenue $665M, adjusted EPS $1.01 (vs. $0.93-$0.95 guidance).
- Adjusted operating margin 25.6%, up y/y due to expense management.
- Tariff-related initiatives to neutralize U.S.-China manufacturing impacts by end of Q2.
- Full year outlook reaffirmed: $4.90-$5.00 EPS, 3%-5% organic growth.
- Q2 organic growth expected 2%-4%, with EPS $1.13-$1.15.

**【Q&A Key Themes】**
- **Tariff Mitigation**: 75%-80% of $135M impact addressed via supply chain shifts; 20% via pricing/supplier changes. 2Q headwinds to resolve by end of Q2.
- **China Performance**: Low single-digit growth (Diagnostics +mid-single, Life Sciences -low-single).
- **Software Growth**: Signals ARR, APV, and net retention metrics exceed 2024 levels; SaaS conversion ~33% complete.
- **Pharma Biotech**: 35% of revenue, reagent demand stable despite headwinds; instrumentation pressured.
- **Reproductive Health**: Newborn screening growth outpaces global birth rates; Genomics England partnership expansion.
- **Long-Term Margin Targets**: 75bps margin expansion (25bps gross, 50bps SG&A leverage) remains intact despite short-term actions.

Revvity (RVTY)-28 Apr 25-2025 Q1 Earnings call transcript

- **Strong Q4 Finish**: 6% organic growth, $1.42 EPS beat, and $151M free cash flow highlight 2024 success.
- **2025 Growth Path**: 3-5% organic growth target, with reagents and software leading recovery.
- **China Focus**: Mid-single-digit growth in immunodiagnostics, cautious on stimulus impact.
- **Margin Resilience**: 20-40bps margin expansion despite $70M+ in new investments.
- **FX Risk**: 1.5% headwind assumed, but cash generation remains robust.


**【CEO Summary Section】**
- **2024 Performance Highlight**: Achieved 6% organic revenue growth in Q4, with adjusted EPS of $1.42, exceeding expectations. Full-year adjusted EPS grew 5% to $4.90.
- **2025 Outlook**: Organic growth expected in the 3% to 5% range, driven by Life Sciences reagents and software. Adjusted operating margin expansion of 20-40 basis points anticipated.
- **Key Trends**: Pharma/biotech spending stabilizing, Life Sciences instruments lagging recovery. China Life Sciences growth expected to align with company average.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Total adjusted revenue $730M (6% organic growth), adjusted operating margin 30.3%, free cash flow $151M.
- **Full-Year 2024**: Adjusted revenue $2.76B (1% organic growth), adjusted EPS $4.90, free cash flow $578M (96% conversion).
- **2025 Guidance**: Revenue $2.8B-$2.85B, adjusted EPS $4.90-$5.00, free cash flow $500M+. FX headwind of 1.5% expected.

**【Q&A Key Questions】**
- **Market Recovery**: Pharma/biotech reagents show mid-single-digit growth, but instruments lag. China stimulus orders seen in Q4, but modest impact assumed.
- **China Strategy**: Reproductive health mid-single-digit growth, Life Sciences instruments expected to recover in 2025. VBP headwinds embedded in guidance.
- **Investments**: $700M+ in R&D, AI, and digital tools to drive long-term growth. Margins expected to expand despite near-term costs.


Actual																	0.67	1.57	2.09	3.96	3.72	2.83	2.31	2.56	2.41	2.32	1.51	1.7	1.01	1.21	1.18	1.25	0.98	1.22	1.28	1.42	1.01	1.18	1.18	1.7
Forecast																	0.557	0.8464	1.5034	3.0116	3.0891	2.4369	1.7401	2.2477	2.115	2.0141	1.4401	1.6388	0.9986	1.1888	1.1937	1.1647	0.9425	1.1219	1.1263	1.3684	0.9487	1.1481	1.141	1.5696
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+20.29%	+85.49%	+39.02%	+31.49%	+20.42%	+16.13%	+32.75%	+13.89%	+13.95%	+15.19%	+4.85%	+3.73%	+1.14%	+1.78%	-1.15%	+7.32%	+3.98%	+8.74%	+13.65%	+3.77%	+6.46%	+2.78%	+3.42%	+8.31%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	652.59M	811.91M	964.22M	1.36B	1.31B	1.23B	1.17B	1.36B	1.26B	1.23B	1.03B	741.42M	675.07M	709.27M	670.95M	696.11M	650.13M	691.89M	684.25M	729.58M	665.00M	720.28M	698.95M	772.06M
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	649.26M	722.01M	840.15M	1.23B	1.21B	1.12B	1.04B	1.27B	1.19B	1.20B	1.02B	1.03B	678.90M	708.38M	695.40M	677.13M	647.25M	690.33M	679.66M	727.91M	661.00M	710.76M	699.36M	764.35M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+0.51%	+12.45%	+14.77%	+10.61%	+8.10%	+9.51%	+12.08%	+7.15%	+5.94%	+2.16%	+1.15%	-27.94%	-0.56%	+0.13%	-3.52%	+2.80%	+0.45%	+0.23%	+0.68%	+0.23%	+0.61%	+1.34%	-0.06%	+1.01%

RVTY

RVTY fundamentals

RVTY Q4 2025 Earnings

Earnings Call

You can ask Aime

RVTY

RVTY fundamentals

RVTY Q4 2025 Earnings

Earnings Call

RVTY Earnings Call Summary for Q4/20258:00 AM on Feb 2, 2026

RVTY Earnings Call Summary for Q3/20258:00 AM on Oct 27, 2025

RVTY Earnings Call Summary for Q2/20258:00 AM on Jul 28, 2025

RVTY Earnings Call Summary for Q1/20258:00 AM on Apr 28, 2025

RVTY Earnings Call Summary for Q4/20248:00 AM on Jan 31, 2025

You can ask Aime